| PlasmidFactory–ArchiMed: investment, 202210 investment by ArchiMed MED Platform II Fund |
2022-10-07 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| Irubis–High-Tech Gründerfonds: investment, 202210 seed financing round totalling €2.8m incl co-lead investor HTGF |
2022-10-06 |
| Assay.Works–Partex: investment, 202209–202210 acquisition €na of Assay.Works by Partex |
2022-09-29 |
| GS Bavaria–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €7-figure incl lead investor HTGF |
2022-09-28 |
| Kupando–High-Tech Gründerfonds: investment, 202209 financing round Series A totalling €13m incl co-investor HTGF |
2022-09-26 |
| Merck (DE)–NMS Group: PARP inhibitor, 202209– collab + license option for PARP1 selective inhibitor NMS-293 |
2022-09-21 |
| Aignostics–Boehringer: investment, 202209 financing round Series A totalling €14m incl existing + co-investor BIVF |
2022-09-15 |
| Aignostics–High-Tech Gründerfonds: investment, 202209 financing round Series A totalling €14m incl existing + co-investor HTGF |
2022-09-15 |
| faCellitate–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €3.7m incl co-lead investor HTGF |
2022-09-07 |
| faCellitate–ROI Verwaltungsgesellschaft: investment, 202209 seed financing round totalling €3.7m incl co-investor ROI (Roland Oetker) |
2022-09-07 |
| faCellitate–Sarstedt: investment, 202209 seed financing round totalling €3.7m incl co-lead investor Sarstedt |
2022-09-07 |
| QLi5 Therapeutics–Atinum Investment: investment, 202209 financing round Series A totalling €10m incl new investor Atinum Investment |
2022-09-07 |
| QLi5 Therapeutics–DAOL Investment: investment, 202209 financing round Series A totalling €10m incl new investor DAOL Investment |
2022-09-07 |
| QLi5 Therapeutics–Khanu Management: investment, 202209 financing round Series A totalling €10m incl new investor KHAN Technology Transfer Fund I |
2022-09-07 |
| QLi5 Therapeutics–SEVERAL: investment, 202209 financing round Series A €10m incl SV Investemnt + KHAN + Atinum Investment + DAOL Investment |
2022-09-07 |
| QLi5 Therapeutics–SV Investment: investment, 202209 financing round Series A totalling €10m incl new investor SV Investment |
2022-09-07 |
| C-mo Medical Solutions–Boehringer: investment, 202209 seed financing round totalling €4.1m incl lead investor BIVF |
2022-09-01 |
| C-mo Medical Solutions–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €4.1m incl co-investor HTGF |
2022-09-01 |
| Central Glass–Evotec: investment, 202208–202211 acquisition of Central Glass Germany GmbH for € 1 by Evotec |
2022-08-25 |
| Genmab–BioNTech: cancer immunotherapy, 202208– collab expansion 50/50 cost + profit sharing developm + commercn monospeific antibodies using HexaBody |
2022-08-05 |
| Polymer Standards Service–Agilent: investment, 202208 acquisition €na of PSS by Agilent |
2022-08-02 |
| Dermagnostix–EU (govt): grant, 202207c EIC accelerator grant €2.5m |
2022-07-22 |
| Dermagnostix–SEVERAL: investment, 202207 seed financing round extension €4.6m from existing + new investors |
2022-07-22 |
| Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF |
2022-07-07 |
| Aurobac Therapeutics–Boehringer: investment, 202207 launch of €40m joint venture Aurobac incl €30m from lead investor Boehringer Ingelheim |
2022-07-06 |
| Ningaloo Biosystems–North Rhine-Westphalia (govt): investment, 202206 pre-seed financing round incl investor NRW.Bank |
2022-06-22 |
| Ningaloo Biosystems–OTHER: investment, 202206 pre-seed financing round incl team of business angels |
2022-06-22 |
| Ningaloo Biosystems–SEVERAL: investment, 202206 pre-seed financing round with business angels + NRW.Bank |
2022-06-22 |
| Carma Fund–Univ Frankfurt: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Innovectis GmbH |
2022-06-21 |
| Kranus Health–High-Tech Gründerfonds: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor HTGF |
2022-06-20 |
| High-Tech Gründerfonds–SEVERAL: investment, 202206 1st closing of HTGF IV at more than €400m incl BMWK + KfW Capital |
2022-06-14 |
| ImCheck Therapeutics–Boehringer: investment, 202206 financing round Series C totalling €80m incl existing + co-investor BIVF |
2022-06-13 |
| Invasight–High-Tech Gründerfonds: investment, 202206 seed financing round totalling CHF4.5m incl co-investor HTGF |
2022-06-07 |
| Merck (DE)–Proxygen: molecular glue degraders, 202206– strategic multi-year collab + license agreem up to €495m plus royalties |
2022-06-02 |
| Partex–Merck (DE): MetAP2 inhibitor, 202205– license to M8891 to Cureteq for AI-based development by Oncoteq from Merck KGaA |
2022-05-30 |
| Tubulis–Germany (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Coparion |
2022-05-03 |
| Tubulis–High-Tech Gründerfonds: investment, 202205 financing round Series B totalling €60m incl existing + co-investor HTGF |
2022-05-03 |
| Boehringer–Roivant: AI-based drug discovery, 202204– collab research €na with VantAI using AI/ML to identify protein degraders |
2022-04-20 |
| Boehringer–CDR-Life: ophthalmic, 202204 collab development existent of antibody fragment-based therapeutic CDR202 for macular degeneration |
2022-04-13 |
| Merck (DE)–Lonza: MAST platform, 202204 acquisiton €na of MAST automated bioreactor sampling system by Merk Life Science from Lonza |
2022-04-05 |
| Boehringer–Celeris Therapeutics: targeted protein degraders, 202204– collab AI-based drug discovery for target of Boehringer |
2022-04-04 |
| Biovox–SEVERAL: investment, 202204 pre-seed financing round with mid-6-figure € amount from business angels |
2022-04-01 |
| Ebenbuild–High-Tech Gründerfonds: investment, 202203 seed financing round totalling €2.5m incl co-lead investor HTGF |
2022-03-31 |
| InfanDx–SEVERAL: investment, 202203 financing round Series A 2nd closing €2m from new + existing investors bringing total Series A to €6m |
2022-03-15 |
| Ayoxxa–btov Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor b-to-v Partners Sàrl |
2022-03-14 |
| Ayoxxa–Equivation: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Equivation-Beteiligungs-GmbH |
2022-03-14 |
| Ayoxxa–North Rhine-Westphalia (govt): investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor NRW.Bank |
2022-03-14 |
| Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Rainer Christine Asset Management GmbH |
2022-03-14 |
| Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Riesner Verwaltungs GmbH |
2022-03-14 |
| Ayoxxa–Prosnav Capital: investment, 202203– financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital NOT REALISED |
2022-03-14 |
| Ayoxxa–ROI Verwaltungsgesellschaft: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Oetker Family Office |
2022-03-14 |
| Ayoxxa–SEVERAL: investment, 202203– financing round providing runway for 3-5 years led by new investor Prosnav Capital NOT REALISED |
2022-03-14 |
| Ayoxxa–Wellington Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Wellington Partners |
2022-03-14 |
| Merck (DE)–Celeris Therapeutics: AI-based drug discovery, 202202– collab research small molecule binders + bifunctional degraders |
2022-03-09 |
| BioEcho–Ampersand: investment, 202203 minority growth equity investment €na from Ampersand Capital Partners |
2022-03-01 |
| In Ovo–Evonik: investment, 202203 financing round totalling €34m incl existing investor Evonik |
2022-03-01 |
| Green Elephant Biotech–Hessen (govt): investment, 202201 pre-seed financing round totalling mid-6-digit € incl lead investor BMH |
2022-02-11 |
| Green Elephant Biotech–OTHER: investment, 202201 pre-seed financing round totalling mid-6-digit € incl business angels as co-investors |
2022-02-11 |
| Green Elephant Biotech–SEVERAL: investment, 202201 pre-seed financing round mid-6-digit € led by BMH with business angels |
2022-02-11 |
| Lindis Blood Care–High-Tech Gründerfonds: investment, 202202 follow-on financing round incl existing + co-lead investor HTGF |
2022-02-09 |
| Lindis Blood Care–MC Services: public relations, 202202 service existent by MC Services |
2022-02-09 |
| Formo–BRAIN Biotech: genome editing technology, 202202– collab using CRISPR BEC platform to scale production of bioidentical milk protein |
2022-02-08 |
| Merck (DE)–eTheRNA: mRNA technology, 202202– collab research using eTheRNA’s mRNA + LNP technologies to evaluate therapeutic feasibility |
2022-02-03 |
| Weriol Group–BRAIN Biotech: investment, 202202 acquisition of 62% of Breatec/Comix for €3.7m upfront + option to acquire remaining shares until 2027Q1 |
2022-02-03 |
| Mainz Biomed–SEVERAL: investment, 202201 public follow-on offering $22.5m+$3.375m with 1.725m+225k common shares at $15/share |
2022-01-28 |
| InstaDeep–BioNTech: investment, 202201 financing round Series B totalling $100m incl co-investor BioNTech |
2022-01-25 |
| BioNTech–Crescendo Biologics: antibody technology, 202201–202512 collab ww up to $790m + royalties using Humabody VH platform for BioNTech targets |
2022-01-10 |
| Crescendo Biologics–BioNTech: investment, 202201 equity investment €na as part of €40m collab upfront payment with cash + equity investment |
2022-01-10 |
| Exelead–Merck (DE): investment, 202201 acquisition $760m in cash by Merck |
2022-01-06 |
| BioNTech–Pfizer: investment, 202201 equity investment $150m by Pfizer in connection with shingles vaccine collaboration |
2022-01-05 |
| Pfizer–BioNTech: mRNA-based vaccines, 202201– collab developm $50m net cash upfront shingles vaccine with shared development cost + profits |
2022-01-05 |
| Chord Therapeutics–Merck (DE): investment, 202112– acquisition of Chord by Merck KGaA from sole investor Omega Funds |
2021-12-20 |
| Brainomix–Boehringer: investment, 202112 financing round Series B totalling £16m incl existing + co-lead investor BIVF |
2021-12-16 |
| Patronus Health–Hessen (govt): grant, 202112 public grant from State of Hesse |
2021-12-16 |
| Patronus Health–MC Services: public relations, 202112 service existent by MC Services |
2021-12-16 |
| Patronus Health–SEVERAL: investment, 202112 pre-seed financing round led by business angel Georg Matheis |
2021-12-16 |
| Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures |
2021-12-08 |
| Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital |
2021-12-07 |
| SciRhom–High-Tech Gründerfonds: investment, 202111 existent HTGF is existing seed investor |
2021-11-30 |
| Dermagnostix–SEVERAL: investment, 202111 7-digit € seed financing round |
2021-11-26 |
| Innerspace–High-Tech Gründerfonds: investment, 202111 2nd seed financing round totalling 7-digit € incl existing investor HTGF |
2021-11-23 |
| Prosion–EU (govt): grant, 202111– EIC Accelerator grant €2.5m |
2021-11-23 |
| Prosion–EU (govt): investment, 202111– option for equity investment from EIC Accelerator |
2021-11-23 |
| Axel Semrau–Trajan: investment, 202111 acquisition €19.85m by Trajan Group |
2021-11-18 |
| Nebula Biocides–High-Tech Gründerfonds: investment, 202111 seed financing round totalling €1.6m incl investor HTGF |
2021-11-10 |
| PhagoMed–BioNTech: investment, 202111 acquisition estimated €150m of PhagoMed by BioNTech |
2021-11-09 |
| Phenox–SHS Capital: investment, 202111 existent portfolio company of SHS |
2021-11-09 |
| Mainz Biomed–SEVERAL: investment, 202111 IPO $10m with 2m common shares at $5/share at Nasdaq Capital Market |
2021-11-04 |
| Cube Biotech–ArchiMed: investment, 202111 acquisition of majority stake by ArchiMed with founders remaining significant shareholders |
2021-11-03 |
| Ariceum Therapeutics–Ipsen: investment, 202010 Ipsen became shareholder by selling rights to satoreotide to Ariceum (then SatoSea Oncology GmbH) |
2021-10-22 |
| Ariceum Therapeutics–Ipsen: satoreotide, 202010 acquisition of all rights from Ipsen which became shareholder of Ariceum (then SatoSea Oncology GmbH) |
2021-10-22 |
| Emergence Therapeutics–Mablink Bioscience: ADC technology, 202110– license for use of PSARlink drug-linker to develop ADC targeting Nectin-4 |
2021-10-21 |
| Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners |
2021-10-14 |
| Computomics–BASF: investment, 202110 acquisition €na of minority stake by BASF Venture Capital GmbH |
2021-10-14 |
| Creapaper–eCapital: investment, 202110 financing round Series B totalling €20m incl existing investor eCapital |
2021-10-06 |
| Cellecta–Merck (DE): CRISPR technology, 202110– license for CRISPR-Cas9 technology to Cellecta |
2021-10-05 |
| Biotest–Grifols: investment, 202109–202204 public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share |
2021-09-17 |
| BRAIN Biotech–SEVERAL: investment, 202109 capital increase €19.6m with 1.99m new shares at €9.85/share to institutional investors |
2021-09-15 |
| Boehringer–Twist Bioscience: antibody drug discovery, 202109– collab using Twist Biopharma antibody phage display libraries against Boehringer targets |
2021-09-09 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
